Lara Malerba

Pesaro, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this?

Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this?

Journal: Expert review of hematology

Published: May 21, 2024

The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL.

The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL.

Journal: American journal of hematology

Published: June 25, 2023

Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study.

Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study.

Journal: Hematological oncology

Published: April 07, 2023

Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL.

Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL.

Journal: Journal of hematology & oncology

Published: April 19, 2022

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study.

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study.

Journal: Leukemia

Published: July 28, 2021

Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report.

Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report.

Journal: Hematological oncology

Published: July 14, 2021

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.

Journal: Leukemia

Published: June 13, 2020

Secondary bone marrow malignancies after adjuvant chemotherapy for breast cancer: a report of 2 cases and a review of the literature.

Secondary bone marrow malignancies after adjuvant chemotherapy for breast cancer: a report of 2 cases and a review of the literature.

Journal: Tumori

Published: February 08, 2016

Enteric-coated mycophenolate sodium: a new option for GHVD prophylaxis?

Enteric-coated mycophenolate sodium: a new option for GHVD prophylaxis?

Journal: European journal of haematology

Published: January 23, 2016

PBSC mobilization in patients with autoimmune diseases: what's next.

PBSC mobilization in patients with autoimmune diseases: what's next.

Journal: European journal of haematology

Published: November 17, 2015

Advancement in high dose therapy and autologous stem cell rescue in lymphoma.

Advancement in high dose therapy and autologous stem cell rescue in lymphoma.

Journal: World journal of stem cells

Published: November 25, 2014

Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma.

Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma.

Journal: Blood

Published: November 08, 2014

Showing 1-12 of 14

Last Updated: 09/26/2026